Puma Biotechnology (PBYI) Set to Announce Earnings on Thursday

Puma Biotechnology (NASDAQ:PBYI) is projected to post its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of $0.09 per share and revenue of $57.50 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $0.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.15. The business had revenue of $56.50 million for the quarter, compared to analysts’ expectations of $53.00 million. Puma Biotechnology had a return on equity of 20.76% and a net margin of 11.50%. On average, analysts expect Puma Biotechnology to post $0.37 EPS for the current fiscal year and $0.14 EPS for the next fiscal year.

Puma Biotechnology Trading Up 0.4%

Shares of NASDAQ PBYI opened at $10.22 on Wednesday. The firm’s 50-day moving average is $9.86 and its 200-day moving average is $7.94. Puma Biotechnology has a 1 year low of $4.57 and a 1 year high of $11.50. The firm has a market capitalization of $527.56 million, a PE ratio of 19.65 and a beta of 1.40.

Insider Activity

In other Puma Biotechnology news, Director Troy Wilson sold 5,000 shares of the business’s stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $9.10, for a total value of $45,500.00. Following the completion of the transaction, the director directly owned 54,750 shares of the company’s stock, valued at approximately $498,225. The trade was a 8.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Alessandra Cesano sold 62,150 shares of the business’s stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $9.12, for a total value of $566,808.00. Following the completion of the transaction, the director directly owned 56,700 shares of the company’s stock, valued at approximately $517,104. The trade was a 52.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 22.20% of the company’s stock.

Wall Street Analysts Forecast Growth

PBYI has been the topic of several recent research reports. Wall Street Zen upgraded Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 15th. TD Cowen upped their target price on shares of Puma Biotechnology from $5.00 to $6.00 and gave the company a “hold” rating in a research note on Friday, August 7th. Finally, Weiss Ratings upgraded shares of Puma Biotechnology from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, October 8th. One analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $6.00.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company focused on developing and commercializing medicines for the treatment of cancer. The company’s lead product is NERLYNX (neratinib), an oral, irreversible tyrosine kinase inhibitor designed to target HER2 and other members of the epidermal growth factor receptor family.

NERLYNX is approved in the United States for the extended adjuvant treatment of adults with early-stage, HER2-positive breast cancer following adjuvant trastuzumab-based therapy.